PDS Biotechnology (PDSB) Total Liabilities (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Total Liabilities came in at $21.2 million in Q4 2025, down 19.4% YoY from $26.4 million in Q4 2024, and down 15.88% on a QoQ basis from $25.3 million in Q3 2025.
PDS Biotechnology (PDSB) Total Liabilities (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Total Liabilities data on file, last reported at $21.2 million in Q4 2025.
- Quarterly Total Liabilities fell 19.4% year-over-year to $21.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.2 million (down 19.4% YoY) and the FY2025 annual result came in at $21.2 million, down 19.4% from the prior year.
- Total Liabilities retreated to $21.2 million in Q4 2025, from $25.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $33.3 million in Q4 2023 to a low of $3.4 million in Q1 2021.
- A 5-year average of $21.2 million and a median of $25.8 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2021 — Total Liabilities tumbled 88.7% — and 2022, when it surged 727.74%.
- Tracing PDSB's Total Liabilities over 5 years: stood at $4.0 million in 2021, then surged by 727.74% to $33.0 million in 2022, then increased by 0.77% to $33.3 million in 2023, then slipped by 20.76% to $26.4 million in 2024, then dropped by 19.4% to $21.2 million in 2025.
- The last three Total Liabilities figures came in at $21.2 million (Q4 2025), $25.3 million (Q3 2025), and $24.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | 12.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.39 Mn |
| Dec 31, 2025 | 21.24 Mn |
| Sep 30, 2025 | 25.25 Mn |
| Jun 30, 2025 | 24.52 Mn |
| Mar 31, 2025 | 24.67 Mn |
| Dec 31, 2024 | 26.35 Mn |
| Sep 30, 2024 | 30.45 Mn |
| Jun 30, 2024 | 29.58 Mn |
| Mar 31, 2024 | 31.82 Mn |
| Dec 31, 2023 | 33.26 Mn |
| Sep 30, 2023 | 32.70 Mn |
| Jun 30, 2023 | 31.31 Mn |
| Mar 31, 2023 | 27.44 Mn |
| Dec 31, 2022 | 33.01 Mn |
| Sep 30, 2022 | 27.83 Mn |
| Jun 30, 2022 | 4.58 Mn |
| Mar 31, 2022 | 5.17 Mn |
| Dec 31, 2021 | 3.99 Mn |
| Sep 30, 2021 | 3.89 Mn |
| Jun 30, 2021 | 4.40 Mn |